Teva Presents New Reslizumab Data at ERS International Congress 2015

Teva Pharmaceutical Industries Ltd.,

today presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS). Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for which Teva is seeking approval in the treatment of asthma in patients with elevated blood eosinophils who are inadequately controlled on an ICS-based regimen. These results were presented as a late-breaking abstract at the 2015 ERS International Congress in Amsterdam.